Clinical studies recruiting near Waukesha

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · ProHealth Waukesha Memorial Hospital · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT05624996 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · UW Cancer Center at ProHealth Care · Alliance for Clinical Trials in Oncology · NCT07321652 Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients
Phase N/A · ProHealth · PrECOG, LLC. · NCT06538038 A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Prohealth Care Inc · Regeneron Pharmaceuticals · NCT06091865 Molecular Genetics Studies of Cancer Patients and Their Relatives
Phase N/A · ProHealth Waukesha Memorial Hospital · City of Hope Medical Center · NCT04185935 Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT06532279 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · ProHealth Waukesha Memorial Hospital · Alliance for Clinical Trials in Oncology · NCT06632327 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · ProHealth Waukesha Memorial Hospital · Alliance for Clinical Trials in Oncology · NCT06876714 Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and S
Phase 3 · ProHealth Waukesha Memorial Hospital · Canadian Cancer Trials Group · NCT06592924 E-Mindfulness Approaches for Living After Breast Cancer
Phase 3 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT06748222 Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggress
Phase 2 · UW Cancer Center at ProHealth Care · National Cancer Institute (NCI) · NCT06649812 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT03180268 Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Plati
Phase 3 · ProHealth Care Inc · Genmab · NCT07564141 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · UW Cancer Center at ProHealth Care · National Cancer Institute (NCI) · NCT05256225 Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-S
Phase 3 · UW Cancer Center at ProHealth Care · National Cancer Institute (NCI) · NCT06498635 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT05327686 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · ProHealth Waukesha Memorial Hospital · ECOG-ACRIN Cancer Research Group · NCT04566328 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · UW Cancer Center at ProHealth Care · NRG Oncology · NCT04852887 mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · ProHealth Waukesha Memorial Hospital · Alliance for Clinical Trials in Oncology · NCT05677490 Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Phase 3 · UW Cancer Center at ProHealth Care · Alliance for Clinical Trials in Oncology · NCT07215910 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · ProHealth Waukesha Memorial Hospital · National Cancer Institute (NCI) · NCT05987241 Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · UW Cancer Center at ProHealth Care · National Cancer Institute (NCI) · NCT05564377 Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Phase 2 · ProHealth Waukesha Memorial Hospital · SWOG Cancer Research Network · NCT04205968 A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Phase 3 · UW Cancer Center at ProHealth Care · National Cancer Institute (NCI) · NCT05675410 Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Meta
Phase 2 · ProHealth Waukesha Memorial Hospital · National Cancer Institute (NCI) · NCT06029270 A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Mult
Phase N/A · TG Therapeutics Investigational Trial Site · TG Therapeutics, Inc. · NCT06433752 Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Diffe
Phase 3 · ProHealth Waukesha Memorial Hospital · National Cancer Institute (NCI) · NCT06422806 BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · ProHealth Waukesha Memorial Hospital · National Cancer Institute (NCI) · NCT05136196

Look up another city

Look up another condition